Mannatech (NASDAQ:MTEX) and Entia Biosciences (OTCMKTS:ERGO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, earnings, dividends and institutional ownership.
Institutional & Insider Ownership
16.0% of Mannatech shares are held by institutional investors. 24.7% of Mannatech shares are held by insiders. Comparatively, 28.3% of Entia Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a breakdown of current ratings and target prices for Mannatech and Entia Biosciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
This table compares Mannatech and Entia Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Mannatech has a beta of 1.72, suggesting that its stock price is 72% more volatile than the S&P 500. Comparatively, Entia Biosciences has a beta of 3.64, suggesting that its stock price is 264% more volatile than the S&P 500.
Mannatech pays an annual dividend of $2.00 per share and has a dividend yield of 10.1%. Entia Biosciences does not pay a dividend. Mannatech has increased its dividend for 2 consecutive years.
Valuation and Earnings
This table compares Mannatech and Entia Biosciences’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mannatech||$176.70 million||0.27||-$1.78 million||N/A||N/A|
|Entia Biosciences||$260,000.00||1.31||-$1.39 million||N/A||N/A|
Entia Biosciences has lower revenue, but higher earnings than Mannatech.
Entia Biosciences beats Mannatech on 7 of the 11 factors compared between the two stocks.
Mannatech Company Profile
Mannatech, Incorporated provides wellness solutions. The company develops, markets, and sells nutritional supplements, topical, skin care and anti-aging products, and weight-management products. It markets its products through network marketing channels in the Americas, Europe/the Middle East/Africa, and the Asia/Pacific. The company was founded in 1993 and is headquartered in Coppell, Texas.
Entia Biosciences Company Profile
Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical foods products in the United States. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical foods, nutraceuticals, cosmetics, and other products. The company's portfolio of formulations include ErgoD2, a pharmaceutical grade organic compound from whole food that contains the micro-nutrients; L-Ergothioneine, a naturally occurring amino acid and master antioxidant; and vitamin D, an antioxidant. In addition, it is also developing products for the chronic kidney disease and other diseases, as well as providing cosmeceuticals and other beauty products under the GROH brand name. Entia Biosciences, Inc. offers its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was founded in 2007 and is headquartered in Sherwood, Oregon.
Receive News & Ratings for Mannatech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mannatech and related companies with MarketBeat.com's FREE daily email newsletter.